Cold Spring Harbor Laboratory

Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows

Retrieved on: 
Thursday, May 19, 2022
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, COVID-19, Feinstein Institute for Medical Research, Inflammation, Serum, Cold, Interleukin 6, TNF, Disease, Blood, Spleen, Medical research, Medicine, Survival, Molecular medicine, Doctor of Philosophy, Autoimmunity, Degenerative disease, Famotidine, Patient, Multimedia, Science, Northwell Health, Injection, Cytokine, Cold Spring Harbor Laboratory, Clinical trial, Adult, Cough, Smell, Institute, Research, Method, Mouse, Brain, Genetics, Credit, Human, Neck, Heartburn, Paper, Safety, Rheumatoid arthritis, LinkedIn, Gut, Mental health, Interleukin, Cancer, Vagus nerve, MD, CEO, Pharmaceutical industry, Vaccine

(Credit: Feinstein Institutes)

Key Points: 
  • (Credit: Feinstein Institutes)
    The preclinical study published in the journal Molecular Medicine shows that famotidine, a histamine 2 receptor (H2R) antagonist, prevents cytokine storm in mice.
  • Investigators found that increased vagus nerve signals were why famotidine injections stopped cytokine storms.
  • By cutting the vagus nerve, known as a vagotomy, it prevented the ability of famotidine to stop the cytokine storms.
  • Now these new results point to a role of the vagus nerve inflammatory reflex in suppressing cytokine storm during COVID-19.

Cold Spring Harbor Laboratory discovers how hormones define brain sex differences

Retrieved on: 
Wednesday, May 4, 2022
Gene, Neuroscience, Aggression, Brain, Biomedical Research, Laboratory, Student, Mouse, Nobel Prize, Male, Neuron, Testosterone, Cold Spring Harbor Laboratory, Human, Cancer, BNST, DNA, Behavior, SPRING, Disease, Education, Nature, Life, Parenting, Cell, Multimedia, Birth control, Vaccine

COLD SPRING HARBOR, N.Y., May 4, 2022 /PRNewswire/ -- Sex hormones play an important role in shaping an animal's behavior, and their influence starts early.

Key Points: 
  • COLD SPRING HARBOR, N.Y., May 4, 2022 /PRNewswire/ -- Sex hormones play an important role in shaping an animal's behavior, and their influence starts early.
  • Early-life hormonal surges help shape the developing brain, establishing circuitry that will influence behavior for a lifetime.
  • Cold Spring Harbor Laboratory Assistant Professor Jessica Tollkuhn , graduate student Bruno Gegenhuber, and their colleagues, have been mapping exactly where estrogen receptors latch onto DNA inside mouse brain cells.
  • Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.

Promising New Universal Coronavirus Vaccine Candidate Discovered

Retrieved on: 
Wednesday, May 4, 2022
Possibility, Cold Spring Harbor Laboratory, Human, Lists of countries and territories, Altmetric, Preprint, Immune system, Machine learning, Organic acid, The New England Journal of Medicine, Patient, BioRxiv, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Vaccine, Animal

INTERLOCHEN, Mich., May 4, 2022 /PRNewswire/ -- Today, Cold Spring Harbor Laboratory published a preprint in BioRxiv of a study conducted by Eric Luellen which identifies a new promising universal coronavirus vaccine candidate. It attenuates 361 out of 365 coronaviruses tested (99%), including all known SARS-CoV-2 variants. The author released the formula to be freely accessible to help poorer countries have greater access to a vaccine to combat the pandemic.

Key Points: 
  • INTERLOCHEN, Mich., May 4, 2022 /PRNewswire/ -- Today, Cold Spring Harbor Laboratory published a preprint in BioRxiv of a study conducted by Eric Luellen which identifies a new promising universal coronavirus vaccine candidate.
  • The author released the formula to be freely accessible to help poorer countries have greater access to a vaccine to combat the pandemic.
  • "Until a universal vaccine is widely available, new variants of this coronavirus and many like it will threaten humankind," said Luellen.
  • The vaccine candidate formula by transforming viral genomic sequence data and analyzing it computationally using machine learning.

DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome

Retrieved on: 
Tuesday, May 3, 2022
Rett syndrome, PTP, Wilson's disease, GLOBE, Company, Food, Orphan Drug Act of 1983, Neurodevelopmental disorder, Patient, Seizure, Degenerative disease, FDA, Cold Spring Harbor Laboratory, Person, Lewis Milestone, Family, Diagnosis, Cancer, Therapy, Media, RTT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enzyme, Disability, Ageing, Marketing, Disease, Achievement, X chromosome, MECP2, CEO, Pharmaceutical industry, PTP1B

Today, DepYmed announces that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations for its lead clinical candidate, a small molecule PTP1B inhibitor for the treatment of patients with Rett Syndrome (RTT).

Key Points: 
  • Today, DepYmed announces that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations for its lead clinical candidate, a small molecule PTP1B inhibitor for the treatment of patients with Rett Syndrome (RTT).
  • FDAs decision to grant these designations for our lead clinical candidate for the treatment of Rett Syndrome is a significant achievement for DepYmed, said Andreas Grill, DepYmeds President & CEO.
  • DepYmed is the first company to develop a new class of orally bioavailable drug candidates that act by inhibiting PTP1B, one of the most important PTP drug targets.
  • One of its lead compounds has shown promising efficacy in preclinical models of Rett syndrome, and the Company hopes to initiate a Phase 1 clinical trial later this year.

Pancreatic Cancer Lab-Grown Human Organoids May Predict Effective Chemotherapy Treatment

Retrieved on: 
Thursday, April 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Method, Cancer, Autoimmunity, LinkedIn, Feinstein Institute for Medical Research, Manuscript, Mental health, 3D, Dana–Farber Cancer Institute, Cold, Multimedia, Genetics, Cold Spring Harbor Laboratory, Lustgarten Foundation for Pancreatic Cancer Research, Research, Doctor of Philosophy, ASA, Medicine, Medical research, CEO, Neoplasm, Organoid, Molecular medicine, Annals of Surgery, Northwell Health, American Surgical Association, Institute, Cancer Institute, Cancer Research UK, Science, Credit, Pancreatic cancer, Patient, Medical imaging, Pharmaceutical industry, MD

It shows the ability to generate organoids from patients, regardless of tumor stage/progression or if the patient had already received chemotherapy.

Key Points: 
  • It shows the ability to generate organoids from patients, regardless of tumor stage/progression or if the patient had already received chemotherapy.
  • The findings suggest that lab testing of organoids may help predict chemotherapy effectiveness and enable patient-specific therapy plans.
  • While pancreatic cancer accounts for three percent of all cancers in the United States, it is responsible for seven percent of all cancer deaths.
  • The study collected 136 tumor samples from 117 patients with pancreatic cancer, including 32 percent of organoids derived from minority populations.

Ultivue Announces New Innovation Team Leadership

Retrieved on: 
Tuesday, April 5, 2022
Software, Research, General Health, Networks, Pharmaceutical, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Cell, Wyss Institute for Biologically Inspired Engineering, Engineering, Biochemistry, Growth, Cold, Cold Spring Harbor Laboratory, University of Pennsylvania, Nature, BS, Doctor of Philosophy, Precision medicine, CEO, Innovation, MD, Harvard Medical School, Science, Solution, GEN, Monash Science Technology Research and Innovation Precinct, CSHL, MD–PhD, Wyss Institute, University, Patient, Method, Medical imaging, Research

Ultivue is thrilled to announce the addition of Professor Je Hyuk Lee in the role of Director of Research and Innovation, as the company adds to its growing expertise in spatial biology.

Key Points: 
  • Ultivue is thrilled to announce the addition of Professor Je Hyuk Lee in the role of Director of Research and Innovation, as the company adds to its growing expertise in spatial biology.
  • Biochemistry from University of Pennsylvania, Philadelphia and a MD, PhD in Cell & Molecular Physiology Tufts School of Medicine, Boston.
  • Ultivue scientists have developed a deceptively simple solution to that problem, and I look forward to leading the team toward a more practical yet information-rich tissue imaging platform in oncology and research."
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Mom's protective behaviors run deep in the brain, new CSHL research finds

Retrieved on: 
Thursday, March 24, 2022
Cell, Locus coeruleus, Laboratory, NA, Cold, Memory, Multimedia, Neuroscience, Mouse, Cold Spring Harbor Laboratory, SPRING, Sleep, Cancer, Wakefulness, Shea, Autism, LC, Nobel Prize, Biomedical Research, Arousal, Vertebrate, Brain, Disorder, Student, Hypothermia, Neuron, Anxiety, Female, Depression, Education, CSHL, Medical imaging

Neuroscientists at Cold Spring Harbor Laboratory (CSHL) now report this resemblance applies in more ways than one.

Key Points: 
  • Neuroscientists at Cold Spring Harbor Laboratory (CSHL) now report this resemblance applies in more ways than one.
  • "We study pup retrieval because it's very reliable and it's done the same way every time," says Shea.
  • The recordings show LC neurons spike in activity at the exact moment a mom touches a pup to retrieve it.
  • Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.

Aanika Biosciences Signals Continued Growth and Expansion of its Food Traceability Technology with New Executive and Science Team Hires

Retrieved on: 
Monday, March 14, 2022
Other Health, Research, General Health, Other Natural Resources, Agriculture, Natural Resources, Fitness & Nutrition, Science, Biotechnology, FDA, Other Science, Health, Safety, Industry, Senior, Business, Seed, Department, Research and development, Bermuda Monetary Authority, Research, Bermuda, Therapy, Molecular biology, World Class IT, SOCOM 4 U.S. Navy SEALs, Memorial Sloan Kettering Cancer Center, Newcastle University, Brooklyn College, CUNY, Bureau of Oceans and International Environmental and Scientific Affairs, Regulatory affairs, Cold Spring Harbor Laboratory, Multimedia, List of life sciences, Leadership, Columbia Business School, MBA, Science, Brown University, Doctor of Philosophy, Health, Cryptologic, Regulation, Technology, BMA, Biology, Graduate Center, CUNY, Fermentation, Biotechnology, CEO, Management, Fine chemical, Medical device, Biochemistry, Intelligence

Aanika Biosciences ( aanikabio.com ), which brings the power of biotech into the supply chain, announced today the expansion of its leadership and science team.

Key Points: 
  • Aanika Biosciences ( aanikabio.com ), which brings the power of biotech into the supply chain, announced today the expansion of its leadership and science team.
  • Aanikas proprietary technology is the first to use biology as a base for re-building and strengthening the safety and security of the worlds food supply.
  • Aanika Biosciences was co-founded in 2018 by Vishaal Bhuyan after he personally experienced the consequences of ordering fresh, ethically sourced seeds and receiving stale, contaminated products instead.
  • He made it is his mission to create a safer food supply by finding a way to track, trace and authenticate products.

Tracy Johnson and Tom Lister join Cold Spring Harbor Laboratory board

Retrieved on: 
Friday, March 11, 2022
Biochemistry, Laboratory, Harvard University, SPRING, Genetics Society of America, Cold Spring Harbor Laboratory, Cold, Jet Aviation, Intelsat, Neuroscience, Howard Hughes Medical Institute, Developmental Biology (journal), Education, Cancer, Chemistry, UCLA, Board, Multimedia, Hospital, HSS, Cell, Duke University, Freescale Semiconductor, Hospital for Special Surgery, Forstmann Little & Company, Biomedical Research, List of life sciences, Ruth L. Kirschstein, Division, CSHL, Duff & Phelps, Student, CEO, Nobel Prize, The Genetics Society, Pharmaceutical industry, Management, Trustee, Permira, Genesys

COLD SPRING HARBOR, N.Y., March 11, 2022 /PRNewswire/ -- On March 10, 2022, the Cold Spring Harbor Laboratory (CSHL) Board of Trustees elected two new members to the private, not-for-profit institution's governing body: Tracy L. Johnson, Ph.D., dean, Division of Life Sciences at UCLA; and Tom Lister, senior partner at the international private equity firm Permira.

Key Points: 
  • COLD SPRING HARBOR, N.Y., March 11, 2022 /PRNewswire/ -- On March 10, 2022, the Cold Spring Harbor Laboratory (CSHL) Board of Trustees elected two new members to the private, not-for-profit institution's governing body: Tracy L. Johnson, Ph.D., dean, Division of Life Sciences at UCLA; and Tom Lister, senior partner at the international private equity firm Permira.
  • "Tom Lister will share valuable experience from the finance sector and insights from his service as a trustee in the healthcare sector."
  • Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.
  • Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians.

DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer

Retrieved on: 
Thursday, March 10, 2022
Stem cell, Industry, Development, Metabolism, Company, Partnership, Research, Cancer research, Therapy, Cold, Cardiovascular disease, Cold Spring Harbor Laboratory, Infection, GLOBE, Diabetes, Patient, American Association for Cancer Research, Media, SRA, Biomedical Research, Immunotherapy, Growth, Rett syndrome, Disease, Lymphatic system, Monash University, Pharmaceutical industry, Vaccine, PTP1B, Immunity, Cancer, Obesity, Neuroscience

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) and the Monash Biomedicine Discovery Institute (“Monash BDI”) at Monash University in Melbourne, Australia announce today that they have entered into a sponsored research agreement (SRA) to explore the potential of the Company’s drug development candidates to treat cancer by targeting a newly discovered intracellular immune checkpoint.

Key Points: 
  • We believe this represents an untapped approach to treating cancers and we anticipate further exploration, commented Andreas Grill, DepYmeds CEO.
  • T cells are a critical part of the bodys immune system that help prevent the growth of cancer cells.
  • One of the important ways that cancers develop occurs when cancer cells acquire the ability to evade recognition by T cells.
  • This new study found that PTP1B is increased in T cells in cancer, limiting their ability to attack tumour cells.